Yazar "Yildiz, M." seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    Improvement of the strength of soils which comprises granular pumice by injection of cement under low pressure
    (Elsevier Science Bv, 2015) Yildiz, M.; Soganci, A. S.
    In this study, improvement of granular pumice soils strength by injection method in Nevsehir City (Turkey) was investigated. In the first phase of the study, the geotechnical properties of granular pumice soils were investigated. The specific density, dry unit weight and water absorption value increased with the decrease of grain size. Thus, it can be seen that the bearing capacity of pumice varies depending on the grain size. In the second level, changes in strength of unconfined compression of injected pumice samples were analysed. The samples taken from the field were prepared to 35, 65 and 85% density, relatively. Pressure of 100 kPa and water/cement ratio of 1.0 was applied to these test samples and the samples were allowed to be cured for a period of 7 and 28 days. The results of the study showed that injected pumice soil reached its maximum strength value with 35% relative density and reached its minimum value with 85% relative density. At the end of 28 days curing period, injected pumice soils prepared with 85% relative density have an equivalent strength to C8 concrete class, and grouted pumice soils prepared with 35% relative density have an equivalent strength to C12 concrete class. (C) 2015 Sharif University of Technology. All rights reserved.
  • Küçük Resim Yok
    Öğe
    A prospectively validated nomogram for predicting the risk of chemotherapy-induced febrile neutropenia: a multicenter study
    (Springer, 2015) Bozcuk, H.; Yildiz, M.; Artac, M.; Kocer, M.; Kaya, C.; Ulukal, E.; Ay, S.
    There is clinical need to predict risk of febrile neutropenia before a specific cycle of chemotherapy in cancer patients. Data on 3882 chemotherapy cycles in 1089 consecutive patients with lung, breast, and colon cancer from four teaching hospitals were used to construct a predictive model for febrile neutropenia. A final nomogram derived from the multivariate predictive model was prospectively confirmed in a second cohort of 960 consecutive cases and 1444 cycles. The following factors were used to construct the nomogram: previous history of febrile neutropenia, pre-cycle lymphocyte count, type of cancer, cycle of current chemotherapy, and patient age. The predictive model had a concordance index of 0.95 (95 % confidence interval (CI) = 0.91-0.99) in the derivation cohort and 0.85 (95 % CI = 0.80-0.91) in the external validation cohort. A threshold of 15 % for the risk of febrile neutropenia in the derivation cohort was associated with a sensitivity of 0.76 and specificity of 0.98. These figures were 1.00 and 0.49 in the validation cohort if a risk threshold of 50 % was chosen. This nomogram is helpful in the prediction of febrile neutropenia after chemotherapy in patients with lung, breast, and colon cancer. Usage of this nomogram may help decrease the morbidity and mortality associated with febrile neutropenia and deserves further validation.